A global, Phase 2, randomized, double-blind, placebo-controlled, response-adaptive dose-ranging study of BMS-986177, an oral factor XIa inhibitor, for the prevention of new ischemic stroke or new covert brain infarction in patients receiving aspirin and clopidogrel following acute ischemic stroke or transient ischemic attack (TIA).
AXIOMATIC SSP is a phase II dose finding trial of a FXIa inhibitor (BMS 986177) added to aspirin and clopidogrel in patients with TIA or minor stroke examining the effect on recurrent stroke. The primary endpoint is a composite of symptomatic stroke and incident covert infarct on MRI imaging during the treatment period.
Global, Phase 2, double-blind, placebo-controlled, response-adaptive randomization (RAR) dose-ranging trial.
Composite of new ischemic stroke and new covert brain infarction (FLAIR + DWI) during the treatment period detected by MRI at 90 days.
Bristol-Myers Squibb and Janssen, LP